A Study of Andrographolide Sulfonate in Patients With Acute Exacerbation of Chronic Bronchitis
NCT ID: NCT03132610
Last Updated: 2017-04-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
240 participants
INTERVENTIONAL
2016-12-01
2018-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Experimental group
Conventional Therapy + Xiyanping injection(andrographolide sulfonate)
andrographolide sulfonate
Conventional Therapy+Xiyanping injection
control group
Conventional Therapy + Xiyanping injection simulation/andrographolide sulfonate simulation(0.9% normal saline)
andrographolide sulfonate simulation
Conventional Therapy+Xiyanping injection simulation
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
andrographolide sulfonate
Conventional Therapy+Xiyanping injection
andrographolide sulfonate simulation
Conventional Therapy+Xiyanping injection simulation
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 2.patients met the acute exacerbation of chronic bronchitis diagnosis;
* 3.Patients with bronchitis were acute attacked 2-6 days,who had a history of chronic bronchitis more than 2 years.
* 4\. Patients compliance is good, written informed consent was obtained from all participants before the study.
Exclusion Criteria
* 2.Pregnancy, lactation, and absence of contraception in women of fertile age.
* 3.Judging by the researchers, Past or present illness of patients may affect to participate in the trial or affect the outcome of the study, including cardio-pulmonary diseases, malignant diseases, autoimmune diseases, hepatorenal disease, blood diseases, nervous system diseases, immune system diseases and endocrine diseases
* 4.After checking, Patients with pulmonary tuberculosis, bronchial asthma, bronchial pneumonia, bronchiectasis, pneumoconiosis, silicosis, lung cancer, pulmonary infiltration or other allergic respiratory diseases and other chronic lung diseases
* 5.Patients using systemic steroids or other immunosuppressive therapy
* 6.Patients with severe cardiopulmonary dysfunction, abnormal liver and kidney function, blood system diseases
* 7.Patients are alcohol (daily drink alcoholic wine is more than 40g) or drug abuse or drug addicts in the past year.
* 8.Patients were participated in any study of drug trials in the last 30 days.
* 9.According to the researchers' judgment, anyone who are not suitable for the study.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Jiangxi Qingfeng Pharmaceutical Co. Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Wei Zhang
Role: PRINCIPAL_INVESTIGATOR
The First Affiliated Hospital of Nanchang University
Ping Xu
Role: PRINCIPAL_INVESTIGATOR
The Fourth Affiliated Hospital of Nanchang University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Wei Zhang
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
JXQF-XYP-1608
Identifier Type: -
Identifier Source: org_study_id